Table 3. Detailed clinical... | American Society of Hematology

Table 3.

Detailed clinical characteristics and hematopoietic reconstitution following BMT

Patient no.	Disease	Patient age, mo	Donor age, y	Cells infused, × 10⁸/kg	Time to PMN recovery, d	Time to PLT recovery, d	Time from BMT, mo	CFCs, per 2 × 10⁴	LTC-ICs, per 10⁶
13	AML	30	14	6.0	9	26	8	11	0
14	Thal	96	3	4.0	10	28	5	25	3.7
15	ALL	120	33	4.7	18	36	9	5	0.4
16	CML	152	25	2.9	12	24	17	3	0
17	Thal	72	46	12.6	13	24	6	13	1.2
18	CML	80	46	7.5	14	35	13	11	0
19	AML	40	28	12.0	23	58	7	6	0
20	AML	108	45	4.5	12	21	11	7	0.5
21	ALL	110	52	6.2	15	38	12	18	1
22	Thal	133	6	2.1	14	32	11	11	0
23	ALL	45	11	3.4	9	21	13	15	2
24	Thal	66	8	5.4	13	26	10	9	0
Median		88	19	5^*	13†	27‡	10.5§	11∥	0.2¶
Range		30-152	3-52	2.1-12.6	9-23	21-58	5-17	3-25	0-3.7

Patient no.	Disease	Patient age, mo	Donor age, y	Cells infused, × 10⁸/kg	Time to PMN recovery, d	Time to PLT recovery, d	Time from BMT, mo	CFCs, per 2 × 10⁴	LTC-ICs, per 10⁶
13	AML	30	14	6.0	9	26	8	11	0
14	Thal	96	3	4.0	10	28	5	25	3.7
15	ALL	120	33	4.7	18	36	9	5	0.4
16	CML	152	25	2.9	12	24	17	3	0
17	Thal	72	46	12.6	13	24	6	13	1.2
18	CML	80	46	7.5	14	35	13	11	0
19	AML	40	28	12.0	23	58	7	6	0
20	AML	108	45	4.5	12	21	11	7	0.5
21	ALL	110	52	6.2	15	38	12	18	1
22	Thal	133	6	2.1	14	32	11	11	0
23	ALL	45	11	3.4	9	21	13	15	2
24	Thal	66	8	5.4	13	26	10	9	0
Median		88	19	5^*	13†	27‡	10.5§	11∥	0.2¶
Range		30-152	3-52	2.1-12.6	9-23	21-58	5-17	3-25	0-3.7

CML indicates chronic myelogenous leukemia. Other abbreviations are explained in the footnote to Table 2

P = .0001

P = .0002

P = .0007

P = NS

P = .007

P = .001